Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy

M.J. Keating, S. O’Brien, S. Lerner, C. Koller, M. Beran, L.E. Robertson, E. J Freireich, E. Estey, H. Kantarjian

Blood (1998) 92 (4): 1165–1171.

https://doi.org/10.1182/blood.V92.4.1165

Published: 1998

Journal Articles

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

M Beran, H Kantarjian, S O'Brien, C Koller, M al-Bitar, S Arbuck, S Pierce, M Moore, JL Abbruzzese, M Andreeff, M Keating, E Estey

Blood (1996) 88 (7): 2473–2479.

https://doi.org/10.1182/blood.V88.7.2473.bloodjournal8872473

Published: 1996

Journal Articles

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]

E Estey, S Kornblau, S Pierce, H Kantarjian, M Beran, M Keating

Blood (1996) 88 (2): 756.

https://doi.org/10.1182/blood.V88.2.756.bloodjournal882756

Published: 1996

Journal Articles

Growth and biologic properties of karyotypically defined subcategories of adult acute lymphocytic leukemia in mice with severe combined immunodeficiency

S Jeha, H Kantarjian, S O'Brien, Y Huh, P Pisa, N Ordonez, M Beran

Blood (1995) 86 (11): 4278–4285.

https://doi.org/10.1182/blood.V86.11.4278.bloodjournal86114278

Published: 1995

Journal Articles

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

S O'Brien, H Kantarjian, M Keating, M Beran, C Koller, LE Robertson, J Hester, MB Rios, M Andreeff, M Talpaz

Blood (1995) 86 (9): 3322–3326.

https://doi.org/10.1182/blood.V86.9.3322.bloodjournal8693322

Published: 1995

Journal Articles

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy

S O'Brien, H Kantarjian, M Beran, LE Robertson, C Koller, S Lerner, MJ Keating

Blood (1995) 86 (4): 1298–1300.

https://doi.org/10.1182/blood.V86.4.1298.bloodjournal8641298

Published: 1995

Journal Articles

Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis

P Marlton, DF Claxton, P Liu, EH Estey, M Beran, M LeBeau, JR Testa, FS Collins, JD Rowley, MJ Siciliano

Blood (1995) 85 (3): 772–779.

https://doi.org/10.1182/blood.V85.3.772.bloodjournal853772

Published: 1995

Journal Articles

Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia

SM Kornblau, HJ Xu, W Zhang, SX Hu, M Beran, TL Smith, J Hester, E Estey, WF Benedict, AB Deisseroth

Blood (1994) 84 (1): 256–261.

https://doi.org/10.1182/blood.V84.1.256.256

Published: 1994

Journal Articles

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]

S O'Brien, H Kantarjian, M Beran, T Smith, C Koller, E Estey, LE Robertson, S Lerner, M Keating

Blood (1993) 82 (6): 1695–1700.

https://doi.org/10.1182/blood.V82.6.1695.1695

Published: 1993

Journal Articles

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent

MJ Keating, S O'Brien, H Kantarjian, W Plunkett, E Estey, C Koller, M Beran, EJ Freireich

Blood (1993) 81 (11): 2878–2884.

https://doi.org/10.1182/blood.V81.11.2878.2878

Published: 1993

Journal Articles

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

HM Kantarjian, M Beran, A Ellis, L Zwelling, S O'Brien, L Cazenave, C Koller, MB Rios, W Plunkett, MJ Keating

Blood (1993) 81 (5): 1146–1151.

https://doi.org/10.1182/blood.V81.5.1146.1146

Published: 1993

Journal Articles

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF

E Estey, PF Thall, H Kantarjian, S O'Brien, CA Koller, M Beran, J Gutterman, A Deisseroth, M Keating

Blood (1992) 79 (9): 2246–2255.

https://doi.org/10.1182/blood.V79.9.2246.2246

Published: 1992

Journal Articles

Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia

HM Kantarjian, EH Estey, S O'Brien, E Anaissie, M Beran, MB Rios, MJ Keating, J Gutterman

Blood (1992) 79 (4): 876–881.

https://doi.org/10.1182/blood.V79.4.876.876

Published: 1992

Journal Articles

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)

EH Estey, R Kurzrock, HM Kantarjian, SM O'Brien, KB McCredie, M Beran, C Koller, MJ Keating, C Hirsch-Ginsberg, YO Huh

Blood (1992) 79 (4): 882–887.

https://doi.org/10.1182/blood.V79.4.882.882

Published: 1992

Journal Articles

Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia

R Mashal, M Shtalrid, M Talpaz, H Kantarjian, L Smith, M Beran, A Cork, J Trujillo, J Gutterman, A Deisseroth

Blood (1990) 75 (1): 180–189.

https://doi.org/10.1182/blood.V75.1.180.180

Published: 1990

Journal Articles

Detection of leukemic clone maturation in vivo by premature chromosome condensation

WN Hittelman, P Agbor, I Petkovic, B Andersson, H Kantarjian, R Walters, C Koller, M Beran

Blood (1988) 72 (6): 1950–1960.

https://doi.org/10.1182/blood.V72.6.1950.1950

Published: 1988

Journal Articles

Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons

M Beran, KB McCredie, MJ Keating, JU Gutterman

Blood (1988) 72 (2): 728–738.

https://doi.org/10.1182/blood.V72.2.728.728

Published: 1988

Journal Articles

Phenotypic and molecular heterogeneity in Philadelphia chromosome- positive acute leukemia

C Hirsch-Ginsberg, C Childs, KS Chang, M Beran, A Cork, J Reuben, EJ Freireich, LC Chang, FJ Bollum, J Trujillo

Blood (1988) 71 (1): 186–195.

https://doi.org/10.1182/blood.V71.1.186.186

Published: 1988

Journal Articles

Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines

M Beran, BS Andersson, P Kelleher, K Whalen, K McCredie, J Gutterman

Blood (1987) 69 (3): 721–726.

https://doi.org/10.1182/blood.V69.3.721.721

Published: 1987

Journal Articles

Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells

M Beran, M Hansson, R Kiessling

Blood (1983) 61 (3): 596–599.

https://doi.org/10.1182/blood.V61.3.596.596

Published: 1983

NARROW

Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]

Growth and biologic properties of karyotypically defined subcategories of adult acute lymphocytic leukemia in mice with severe combined immunodeficiency

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy

Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis

Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF

Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)

Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia

Detection of leukemic clone maturation in vivo by premature chromosome condensation

Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons

Phenotypic and molecular heterogeneity in Philadelphia chromosome- positive acute leukemia

Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines

Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only